Drugs
Effect of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Lipoprotein(a) Levels: An Umbrella Review of Meta-analyses of Randomized Controlled Trials.
Wenmei Qiao, Yunfei Feng, Zhifeng Wen, Lei Dou, Yongze Li
Published: 202610.1007/s40265-025-02274-x
Abstract
BACKGROUND: Elevated lipoprotein(a) [Lp(a)] is a genetically determined, causal risk factor for atherosclerotic cardiovascular disease, but effective therapies remain limited. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are prima…
Preview only. Read the full abstract at the source